SCHEMBL662301

SCHEMBL662301

C[CH]CN1CCCCCc2ccccc21

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
CHRM2 P08172 9/20 0.51
CHRM4 P08173 9/20 0.51
CHRM1 P11229 9/20 0.51
CHRM3 P20309 9/20 0.51
TSHR P16473 1/20 0.49
USP2 O75604 1/20 0.47
CDK4 P11802 1/20 0.47
ALOX15 P16050 1/20 0.47
CCND1 P24385 1/20 0.47
HDAC1 Q13547 2/20 0.46
HDAC6 Q9UBN7 2/20 0.46
HDAC8 Q9BY41 1/20 0.46
GAA P10253 1/20 0.44
HDAC3 O15379 1/20 0.43
HDAC2 Q92769 1/20 0.43
KDM4E B2RXH2 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3357713 0.82 ALDH1A1 (0.51) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL24721277 0.81 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL24721489 0.81 ALDH1A1 (0.63) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL12626929 0.80 ALDH1A1 (0.65) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL4631036 0.77 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL30678342 0.77 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL5970702 0.77 ALDH1A1 (0.57) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL12411280 0.76 ALDH1A1 (0.56) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL3233063 0.74 ALDH1A1 (0.72) ALDH1A1MEN1KMT2ACHRM2CHRM4
SCHEMBL30487785 0.74 ALDH1A1 (0.72) ALDH1A1MEN1KMT2ACHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP claimed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US claimed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP claimed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO claimed
EP-3827820-A1 BRIVARACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2021-06-02 EP disclosed
EP-3260118-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2021-03-24 EP disclosed
US-10806717-B2 Methods and compositions for improving cognitive function THE JOHNS HOPKINS UNIVERSITY (US) 2020-10-20 US disclosed
EP-3610890-A1 METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA The Johns Hopkins University (US) 2020-02-19 EP disclosed
US-10154988-B2 Methods and compositions for treating schizophrenia THE JOHNS HOPKINS UNIVERSITY (US) 2018-12-18 US disclosed
EP-3400934-A1 LEVETIRACETAM FOR IMPROVING COGNITIVE FUNCTION The Johns Hopkins University (US) 2018-11-14 EP disclosed
EP-2346500-B1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION UNIV JOHNS HOPKINS (US) 2017-05-17 EP disclosed
US-20160038463-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION THE JOHNS HOPKINS UNIVERSITY 2016-02-11 US disclosed
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2010-04-22 US disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed
WO-2006090275-A1 TREATMENT OF INCONTINENCE PFIZER LIMITED (GB) 2006-08-31 WO disclosed
EP-1620399-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2006-02-01 EP disclosed
WO-2004087658-A1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB, S.A. (BE) 2004-10-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10806717-B2 Methods and compositions for improving cognitive function GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885MEN1 3878/4885KMT2A 140/4885
US-20160038463-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION GRIN2A, CHRNA2, SYNGR2 ALDH1A1 2177/4885MEN1 3878/4885KMT2A 140/4885
US-10154988-B2 Methods and compositions for treating schizophrenia RAB2A, SYNGR2, GRIN2A ALDH1A1 3381/4885MEN1 4080/4885KMT2A 592/4885
US-20100099735-A1 METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION BACE2, RAB2A, VAMP8 ALDH1A1 2819/4885MEN1 4554/4885KMT2A 116/4885
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 ALDH1A1 308/4885MEN1 2163/4885KMT2A 1267/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 ALDH1A1 308/4885MEN1 2163/4885KMT2A 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.